UBS Lowers Enhabit Price Target to $8.50 from $10, Maintains Neutral Rating
ByAinvest
Sunday, Aug 10, 2025 6:53 am ET1min read
EHAB--
Home health services saw admissions grow by 1.3% year over year, while hospice care delivered its sixth consecutive quarter of growth with an average daily census rising by 12.3%. The company also strengthened its balance sheet by reducing bank debt and increasing liquidity. Enhabit opened three de novo locations, including one home health and two hospice facilities, and continued its de-levering efforts, reducing bank debt by $10.0 million in the quarter.
However, UBS has recently lowered the price target for Enhabit to $8.50 from $10, maintaining a Neutral rating. The analyst highlighted the ongoing challenges facing the home health industry, including rate cuts, and advised caution. Enhabit is focused on addressing these issues, but the analyst noted that the company's efforts to mitigate the impact of rate cuts may take time to materialize.
Enhabit's financial performance for the second quarter was robust, with strong growth in revenue and Adjusted EBITDA. However, the company faces significant challenges in the home health industry, particularly concerning rate cuts. Investors should closely monitor the company's efforts to address these challenges and the impact on its financial performance.
References:
[1] https://www.businesswire.com/news/home/20250805819765/en/Enhabit-Reports-Second-Quarter-2025-Financial-Results
UBS--
UBS has lowered the price target for Enhabit (EHAB) to $8.50 from $10 and maintains a Neutral rating. The Q2 results were positive, but the company is focused on addressing the home health rate cut. The analyst highlights the ongoing challenges facing the home health industry and advises caution.
Enhabit, Inc. (NYSE: EHAB), a leading provider of home health and hospice care, reported its second-quarter 2025 financial results, showcasing a positive performance despite industry challenges. The company reported net service revenue of $266.1 million, net income of $5.2 million, and Adjusted EBITDA of $26.9 million for the quarter ended June 30, 2025. These results reflect strong execution of strategic priorities, with sequential and year-over-year growth in revenue and Adjusted EBITDA.Home health services saw admissions grow by 1.3% year over year, while hospice care delivered its sixth consecutive quarter of growth with an average daily census rising by 12.3%. The company also strengthened its balance sheet by reducing bank debt and increasing liquidity. Enhabit opened three de novo locations, including one home health and two hospice facilities, and continued its de-levering efforts, reducing bank debt by $10.0 million in the quarter.
However, UBS has recently lowered the price target for Enhabit to $8.50 from $10, maintaining a Neutral rating. The analyst highlighted the ongoing challenges facing the home health industry, including rate cuts, and advised caution. Enhabit is focused on addressing these issues, but the analyst noted that the company's efforts to mitigate the impact of rate cuts may take time to materialize.
Enhabit's financial performance for the second quarter was robust, with strong growth in revenue and Adjusted EBITDA. However, the company faces significant challenges in the home health industry, particularly concerning rate cuts. Investors should closely monitor the company's efforts to address these challenges and the impact on its financial performance.
References:
[1] https://www.businesswire.com/news/home/20250805819765/en/Enhabit-Reports-Second-Quarter-2025-Financial-Results

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet